Literature DB >> 9399395

Inflammatory bowel diseases: health care and costs in Sweden in 1994.

P Blomqvist1, A Ekbom.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) has highly variable course and severity. Since comprehensive data on its impact are scarce, we analyzed all IBD care and costs in Sweden (population, 8.8 million).
METHODS: A cross-sectional observational study, using national registers and surveys on ambulatory care, hospital admissions, medication, sickness leave, and early retirement for IBD in 1994, was carried out. We calculated direct health care costs and indirect 1-year costs caused by morbidity.
RESULTS: Ambulatory care was concentrated to specialists in internal medicine at hospitals. One-fourth of the patients accounted for 48% of 1994 hospital admissions. Medication was predominantly aminosalicylates and steroids. Sickness leave episodes were long--on average, 6 weeks. Although uncommon, early retirements lasted 14 years on average. With regard to the underlying prevalence, the use of health care and compensations by Crohn's disease patients was two to four times that of patients with ulcerative colitis. Morbidity took 68% of total costs. Among direct costs, admissions accounted for 58%. Neither complications nor surveillance added much.
CONCLUSION: Ulcerative colitis is twice as common as Crohn's disease. In health care use, these roles are reversed. Since morbidity causes two-thirds of the costs, comprehensive analyses, including indirect costs, are necessary when evaluating new diagnostics and therapies.

Entities:  

Mesh:

Year:  1997        PMID: 9399395     DOI: 10.3109/00365529709002993

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  29 in total

1.  Health care costs of complex perianal fistula in Crohn's disease.

Authors:  M Chaparro; C Zanotti; P Burgueño; I Vera; F Bermejo; I Marín-Jiménez; C Yela; P López; M D Martín; C Taxonera; B Botella; R Pajares; A Ponferrada; M Calvo; A Algaba; L Pérez; B Casis; J Maté; J Orofino; N Lara; M García-Losa; X Badia; J P Gisbert
Journal:  Dig Dis Sci       Date:  2013-09-13       Impact factor: 3.199

Review 2.  Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.

Authors:  Antonio Di Sabatino; Lucio Liberato; Monia Marchetti; Paolo Biancheri; Gino R Corazza
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

3.  Costs of inflammatory bowel disease in Germany.

Authors:  Renee Stark; Hans-Helmut König; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  The pharmacoeconomics of biologic therapy for IBD.

Authors:  Russell D Cohen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

5.  Health care resource use and costs in Crohn's disease before and after infliximab therapy.

Authors:  Dustin E Loomes; Christopher Teshima; Philip Jacobs; Richard N Fedorak
Journal:  Can J Gastroenterol       Date:  2011-09       Impact factor: 3.522

Review 6.  Cost of illness of Crohn's disease.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 7.  Hematopoietic cell transplantation for Crohn's disease; is it time?

Authors:  Y Leung; M Geddes; J Storek; R Panaccione; P L Beck
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

8.  Intestinal surgery for Crohn's disease: predictors of recovery, quality of life, and costs.

Authors:  Marco Scarpa; Cesare Ruffolo; Domenico Bassi; Riccardo Boetto; Renata D'Incà; Andrea Buda; Giacomo C Sturniolo; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2009-09-25       Impact factor: 3.452

Review 9.  Prevalence and outcome of anemia after restorative proctocolectomy: a clinical literature review.

Authors:  Amosy E M'Koma; Paul E Wise; David A Schwartz; Roberta L Muldoon; Alan J Herline
Journal:  Dis Colon Rectum       Date:  2009-04       Impact factor: 4.585

Review 10.  Use of the tumor necrosis factor-blockers for Crohn's disease.

Authors:  Alan B R Thomson; Milli Gupta; Hugh J Freeman
Journal:  World J Gastroenterol       Date:  2012-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.